Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis

  title={Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis},
  author={Robert G Josse and Aliya A. Khan and Daniel Ngui and Marla Shapiro},
  journal={Current Medical Research and Opinion},
  pages={205 - 216}
Abstract Background: According to the 2010 Osteoporosis Canada Clinical Practice Guidelines, denosumab is a first-line option for the pharmacological management of postmenopausal osteoporosis (PMO), along with several therapeutics that may be more familiar to family practice doctors: bisphosphonates, raloxifene, teriparatide, and hormone therapy. Denosumab is indicated for postmenopausal patients at high risk for fracture or others who have failed, or are intolerant to, other osteoporosis… 

Three-year results of denosumab treatment for osteoporosis in women with rheumatoid arthritis and primary osteoporosis: A clinical observational study

Denosumab treatment for osteoporosis had a similar efficacy over 3 years among women with RA and PO, and the ΔBMD for the lumbar spine, total hip, and femoral neck as well as ΔP1NP and ΔTRACP-5b did not differ significantly between the two groups at any time points.

New and emerging treatments for osteoarthritis management: will the dream come true with personalized medicine?

An exciting new era in DMOAD development is within reach, provided future clinical trials are sufficiently powered, systematically designed, use the appropriate evaluation tools, and target the appropriate categories of OA patients.

Effects of denosumab treatment on bone mineral density and joint destruction in patients with rheumatoid arthritis

The existing combined modality therapy with denosumab might be effective for osteoporosis and joint destruction in patients with RA.

Drug/Agent Treatments for Osteoarthritis: Present and Future

Combining therapeutics at both local and systemic levels to impact both symptoms and joint structural changes will likely be the future strategy instead of a sole drug, at least at the beginning of the treatment.

Generalized osteoporosis of mixed origin with severe compression fractures and pain syndrome

Denosumab is a new class of osteoporosis treatment called a human monoclonal antibody that prevents RANKL-RANK interaction and thereby inhibits osteoclast formation, demonstrates significant efficacy for vertebral, nonvertebral and hip fracture risk reduction.

The Calcium Culprit: A Case of Denosumab-induced Hypocalcemia

A male patient, with a past medical history negative for the aforementioned conditions, who presented with right shoulder pain and was found to be severely hypocalcemic secondary to denosumab is presented.

Radiological Evaluation of the Efficacy of Denosumab as a Treatment for Giant-cell Tumour of Bone with Histopathological Correlation

Denosumab is an efficacious treatment for GCTB in terms of clinical, radiological, and histopathological response, with no major complications documented in the present study.

Dietary Collagen Hydrolysates Retard Estrogen Deficiency-Induced Bone Loss through Blocking Osteoclastic Activation and Enhancing Osteoblastic Matrix Mineralization

Pangasius hypophthalmus fish skin collagen hydrolysates (fsCH) inhibited ovariectomy (OVX)-induced bone loss and may be a natural compound retarding postmenopausal osteoporosis and pathological osteoresorptive disorders.

Pharmacologic management of osteoporosis.

An overview of the medications approved by the Food and Drug Administration to treat and prevent osteoporosis is provided.



Denosumab for the Management of Postmenopausal Osteoporosis

The introduction of denosumab into clinical practice provides physicians with another option for the treatment of postmenopausal osteoporosis, and the twice-yearly dosing regimen has the potential to improve adherence.

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy

  • D. KendlerC. Roux H. Bone
  • Medicine
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2010
Transition to denosumab produced greater increases in BMD at all measured skeletal sites and a greater reduction in bone turnover than did continued alendronate with a similar safety profile in both groups.

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

The data suggest that risedronate therapy is effective and well tolerated in the treatment of women with established postmenopausal osteoporosis.

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.

CONTEXT Denosumab is an investigational fully human monoclonal antibody against receptor activator of nuclear factor-kappaB ligand, a mediator of osteoclastogenesis and osteoclast survival.

Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.

Denosumab reduced the incidence of new vertebral and hip fractures in postmenopausal women with osteoporosis at higher risk for fracture, and these results highlight the consistent antifracture efficacy of denosumAB in patients with varying degrees of fracture risk.

Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta‐analysis

Low evidence quality showed low evidence quality that supported the hypothesis the denosumab vs. alendronate treatment was more effective in increasing bone mass but could not reduce the fracture risk to a greater extent than 70 mg Aln QW therapy, and the Den SC Q6M therapy did not increase the risks of neoplasms and infections compared with AlnQW.

Bone remodeling in postmenopausal women who discontinued denosumab treatment: Off‐treatment biopsy study

The results of this study showed normal histology and bone remodeling similar to those observed in untreated postmenopausal women with osteoporosis, and confirm that the effects of denosumab on bone turnover at the tissue level are fully reversible.

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

  • R. EastellC. Christiansen S. Cummings
  • Medicine, Biology
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2011
The BTM response pattern with denosumab is unique and should be appreciated by physicians to monitor this treatment effectively, and the correlations between changes in BTMs and bone mineral density (BMD) are significant.

Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

In postmenopausal women with low BMD, the effects of 60 mg denosumab treatment for 24 months on BMD and BTM are reversible upon discontinuation, reflecting its biological mechanism of action.